ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
作者信息
Dietz Michelle V, Madsen Eva V E
机构信息
Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
出版信息
Ann Surg Oncol. 2022 Oct;29(11):6577-6578. doi: 10.1245/s10434-022-11842-4. Epub 2022 Apr 29.
Abstract
摘要
相似文献
1
ASO Author Reflections: The Timing of Onset of Peritoneal Metastases from Colorectal Carcinoma Is Not an Independent Predictor of Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.ASO作者反思：结直肠癌腹膜转移的发病时间并非是经细胞减灭术联合腹腔内热化疗后生存结局的独立预测因素。
Ann Surg Oncol. 2022 Oct;29(11):6577-6578. doi: 10.1245/s10434-022-11842-4. Epub 2022 Apr 29.
2
ASO Author Reflections: Is Systemic Chemotherapy Useful in Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Peritoneal Metastases? A Propensity Score Analysis.ASO作者反思：全身化疗对接受减瘤手术和热灌注化疗（HIPEC）治疗的结直肠癌腹膜转移患者是否有用？一项倾向评分分析。
Ann Surg Oncol. 2024 Mar;31(3):2008-2009. doi: 10.1245/s10434-023-14468-2. Epub 2023 Oct 18.
3
ASO Author Reflections: Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).ASO作者反思：微卫星和RAS/RAF突变状态作为接受减瘤手术和腹腔内热灌注化疗（HIPEC）治疗的结直肠癌腹膜转移的预后因素
Ann Surg Oncol. 2022 Jun;29(6):3418-3419. doi: 10.1245/s10434-021-11057-z. Epub 2021 Nov 6.
4
ASO Author Reflections: HIPEC Immunogenic Changes Could be Further Exploited by Immunotherapy to Treat Peritoneal Metastases from Colorectal Cancer.ASO作者反思：热灌注化疗的免疫原性变化可通过免疫疗法进一步利用，以治疗结直肠癌的腹膜转移。
Ann Surg Oncol. 2023 May;30(5):2664-2665. doi: 10.1245/s10434-023-13254-4. Epub 2023 Feb 17.
5
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand?细胞减灭术和腹腔热灌注化疗治疗结直肠腹膜转移：我们处于什么位置？
Cancer. 2023 Feb 15;129(4):495-502. doi: 10.1002/cncr.34567. Epub 2022 Dec 16.
6
ASO Author Reflections: Addressing Hospital-Based Disparities in Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) and Survival in Patients with Isolated Colorectal Peritoneal Metastases.ASO作者反思：解决基于医院的孤立性结直肠腹膜转移患者在接受细胞减灭术联合热灌注化疗（CRS-HIPEC）及生存方面的差异问题。
Ann Surg Oncol. 2024 Jun;31(6):3787-3788. doi: 10.1245/s10434-024-15193-0. Epub 2024 Mar 18.
7
ASO Author Reflections: Significance of Primary Tumor Location and Genomic Alterations in Colorectal Peritoneal Metastases and Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemotherapy.ASO作者反思：原发性肿瘤位置和基因组改变在结直肠癌腹膜转移及细胞减灭术-热灌注化疗中的意义
Ann Surg Oncol. 2023 Jul;30(7):4471-4472. doi: 10.1245/s10434-023-13522-3. Epub 2023 Apr 27.
8
Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases?结直肠癌腹膜转移行细胞减灭术和腹腔热灌注化疗时，是否应将腹膜外疾病史作为禁忌证？
Dis Colon Rectum. 2018 Sep;61(9):1026-1034. doi: 10.1097/DCR.0000000000001156.
9
Synchronous Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Liver and Peritoneal Metastases: A Systematic Review and Meta-analysis.同步肝切除、细胞减灭术和腹腔内热灌注化疗治疗结直肠癌肝和腹膜转移：系统评价和荟萃分析。
Dis Colon Rectum. 2021 Jun 1;64(6):754-764. doi: 10.1097/DCR.0000000000002027.
10
Evolution of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: 8-Year Single-Institutional Experience.结直肠腹膜转移的细胞减灭术和腹腔热灌注化疗的演变：8 年单中心经验。
Dis Colon Rectum. 2019 Oct;62(10):1195-1203. doi: 10.1097/DCR.0000000000001456.
本文引用的文献
1
Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma.结直肠癌腹膜转移患者同步性与异时性发生时行细胞减灭术联合腹腔热灌注化疗的生存结局。
Ann Surg Oncol. 2022 Oct;29(11):6566-6576. doi: 10.1245/s10434-022-11805-9. Epub 2022 May 5.
2
Treatment Strategies and Prognosis of Patients With Synchronous or Metachronous Colorectal Peritoneal Metastases: A Population-Based Study.同步或异时性结直肠腹膜转移患者的治疗策略和预后：一项基于人群的研究。
Ann Surg Oncol. 2021 Dec;28(13):9073-9083. doi: 10.1245/s10434-021-10190-z. Epub 2021 Jun 2.
3
The importance of synchronicity in the management of colorectal peritoneal metastases with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.同步性在结直肠腹膜转移的细胞减灭术和腹腔热灌注化疗中的重要性。
World J Surg Oncol. 2020 Jan 13;18(1):10. doi: 10.1186/s12957-020-1784-4.
4
Different variables predict the outcome of patients with synchronous versus metachronous metastases of colorectal cancer.不同变量预测结直肠癌同时性与异时性转移患者的结局。
Clin Transl Oncol. 2020 Aug;22(8):1399-1406. doi: 10.1007/s12094-019-02277-7. Epub 2020 Jan 8.
5
Impact of Synchronous Versus Metachronous Onset of Colorectal Peritoneal Metastases on Survival Outcomes After Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Multicenter, Retrospective, Observational Study.结直肠腹膜转移同步与异时发生对细胞减灭术（CRS）联合腹腔热灌注化疗（HIPEC）后生存结局的影响：一项多中心、回顾性、观察性研究。
Ann Surg Oncol. 2019 Jul;26(7):2210-2221. doi: 10.1245/s10434-019-07294-y. Epub 2019 Mar 15.
Zotero 插件